Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study.

MLA

Meric-Bernstam, Funda, et al. “Zanidatamab, a Novel Bispecific Antibody, for the Treatment of Locally Advanced or Metastatic HER2-Expressing or HER2-Amplified Cancers: A Phase 1, Dose-Escalation and Expansion Study.” The Lancet. Oncology, vol. 23, no. 12, Dec. 2022, pp. 1558–70. EBSCOhost, https://doi.org/10.1016/S1470-2045(22)00621-0.

APA

Meric-Bernstam, F., Beeram, M., Hamilton, E., Oh, D.-Y., Hanna, D. L., Kang, Y.-K., Elimova, E., Chaves, J., Goodwin, R., Lee, J., Nabell, L., Rha, S. Y., Mayordomo, J., El-Khoueiry, A., Pant, S., Raghav, K., Kim, J. W., Patnaik, A., Gray, T., … Lee, K.-W. (2022). Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study. The Lancet. Oncology, 23(12), 1558–1570. https://doi.org/10.1016/S1470-2045(22)00621-0

Chicago

Meric-Bernstam, Funda, Muralidhar Beeram, Erika Hamilton, Do-Youn Oh, Diana L Hanna, Yoon-Koo Kang, Elena Elimova, et al. 2022. “Zanidatamab, a Novel Bispecific Antibody, for the Treatment of Locally Advanced or Metastatic HER2-Expressing or HER2-Amplified Cancers: A Phase 1, Dose-Escalation and Expansion Study.” The Lancet. Oncology 23 (12): 1558–70. doi:10.1016/S1470-2045(22)00621-0.